Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY10.67 CNY
Change Today +0.71 / 7.13%
Volume 16.0M
As of 3:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

harbin pharmaceutical grp-a (600664) Snapshot

Open
CNY10.18
Previous Close
CNY9.96
Day High
CNY10.69
Day Low
CNY10.00
52 Week High
06/17/15 - CNY17.20
52 Week Low
08/29/14 - CNY6.60
Market Cap
20.5B
Average Volume 10 Days
24.5M
EPS TTM
CNY0.15
Shares Outstanding
1.9B
EX-Date
08/26/15
P/E TM
69.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for HARBIN PHARMACEUTICAL GRP-A (600664)

Related News

No related news articles were found.

harbin pharmaceutical grp-a (600664) Related Businessweek News

No Related Businessweek News Found

harbin pharmaceutical grp-a (600664) Details

Harbin Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and trading of pharmaceutical in China and internationally. The company offers antibiotics, small-molecular drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, animal vaccines, and medicine circulations under the Hongyan Yaopin, Guangwei, Renmin Tongtai, Hayao Shengwu, Baohulu, Manshanhong, Hutong, Hayaoliu, Gaizhonggai, Sanchine, Shiyitang, and Hayao brands. Its APIs include penicillin, cephalosporin, and intermediates. Harbin Pharmaceutical Group Co., Ltd. is based in Harbin, China.

harbin pharmaceutical grp-a (600664) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

harbin pharmaceutical grp-a (600664) Key Developments

Harbin Pharmaceutical Group Co., Ltd., Board Meeting, Jul 20, 2015

Harbin Pharmaceutical Group Co., Ltd., Board Meeting, Jul 20, 2015. Agenda: To discuss and approve issues including the incentive plan of restricted shares (Draft) and its abstract; to approve the evaluation and management measures on implementation of incentive plan of restricted shares; and to approve the proposal of requesting the shareholders meeting to authorize the directorate to handle relevant issues of incentive plan of restricted shares.

Harbin Pharmaceutical Group Co., Ltd., Board Meeting, Jul 17, 2015

Harbin Pharmaceutical Group Co., Ltd., Board Meeting, Jul 17, 2015. Agenda: To discuss and approve issues including the proposal of changing director; to consider the proposal of adjusting members of Special Committees of Directorate; and to consider the proposal of appointing senior management members.

Harbin Pharmaceutical Group Co., Ltd., Special/Extraordinary Shareholders Meeting, Aug 03, 2015

Harbin Pharmaceutical Group Co., Ltd., Special/Extraordinary Shareholders Meeting, Aug 03, 2015. Agenda: To discuss the proposal of electing directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600664:CH CNY10.67 CNY +0.71

600664 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China BCT Pharmacy Group Inc $0.0062 USD 0.00
Kirin Holdings Co Ltd ¥1,777 JPY +57.50
Roche Holding AG SFr.263.20 CHF -3.80
View Industry Companies
 

Industry Analysis

600664

Industry Average

Valuation 600664 Industry Range
Price/Earnings 74.3x
Price/Sales 1.1x
Price/Book 2.2x
Price/Cash Flow 73.8x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARBIN PHARMACEUTICAL GRP-A, please visit www.hayao.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.